Organized around the use of natural plasma protease inhibitors for the management of sepsis and cancer, ProThera Biologics is developing novel products that exploit the promise of personalized medicine by leveraging on its proprietary technology of natural serine protease inhibitor proteins. With an emphasis on currently unmet medical needs, the firm is developing integrated theranostic and therapeutic biomolecules for sepsis, anthrax intoxication and cancer. Theranostics represent a new market area which utilize predictive tests to make critical, personalized treatment decisions. By combining both the predictive test and the effective replacement therapy of natural occuring inter-alpha inhibitors, ProThera offers a rational targeted solution to treat deadly sepsis. The firm is developing a new predictive biomarker and therapeutic agent based on human plasma derived inter-alpha inhibitor proteins (II) for the effective management of severe sepsis. This is a natural serine protease inhibitor found in relatively high concentration in plasma and has been shown to play a role in inflammation, wound healing, and cancer metastasis.
